Darusentan, Gilead Sciences‘ endothelin receptor antagonist (ERA) for the treatment of resistant hypertension, failed to achieve its co-primary efficacy endpoints in a Phase III trial. The endpoints were change from baseline to week 14 in trough sitting systolic blood pressure (SBP) and diastolic blood pressure (DBP) compared to placebo. The failure likely means an end to development of Darusentan. The international Phase III double-blind, placebo- and active-controlled, parallel group ...